Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data

被引：33

作者：

Kok, Marleen

Voorwerk, Leonie

Horlings, Hugo

Sikorska, Karolina

van der Vijver, Koen

Slagter, Maarten

Warren, Sarah

Ong, SuFey

Wiersma, Terry

Russell, Nicola

Lalezari, Ferry

de Maaker, Michiel

Kemper, Inge

Mandjes, Ingrid A.

Chalabi, Myriam

Sonke, Gabe S.

Salgado, Roberto

Linn, Sabine C.

Schumacher, Ton

Blank, Christian U.

机构：

[1] Netherlands Canc Inst, Amsterdam, Netherlands

[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands

[3] NanoString Technol Inc, Seattle, WA USA

[4] NanoString, Seattle, WA USA

[5] NKI, Amsterdam, Netherlands

[6] BOOG Study Ctr, Amsterdam, Netherlands

[7] Univ Antwerp, Ctr Oncol Res CORE, Campus Sint Augustinus, Antwerp, Belgium

[8] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.1012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1012

引用

页数：1